This demonstrates the clinical relevance of galectin-1, alpha-1-microglobulin, and galectin-9 in helping clinicians understand the future trajectory of their patients with PAD in terms of MACE risk. This evidence concerns the gene LGALS1 and peripheral arterial disease.